Nautilus Biotechnology reports Q2 EPS (12c) vs (14c) last year

Operating expenses were $17.1 million for the second quarter of 2025, a 18% decrease compared to $20.8 million for the corresponding prior year period. Cash, cash equivalents, and investments were $179.5 million as of June 30, 2025. “In Q2, we achieved major milestones that underscore the continued advancement of our platform,” said Sujal Patel, CEO of Nautilus Biotechnology (NAUT). “Not only did we continue our momentum across both targeted and broadscale proteomic development efforts, but we also publicly shared the first scientific manuscript to feature novel data generated using the Nautilus Platform. The manuscript represents nearly a decade of pioneering work by our team and collaborators. In it, we introduce and validate application of our Iterative Mapping method showing that it can measure proteoforms at a resolution and breadth never before possible.”